Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
May 26th, 2023
Tumor organoids have revolutionized cancer research and the approach to personalized medicine. They represent a clinically relevant tumor model that allows researchers to stay one step ahead of the tumor in the clinic. This protocol establishes tumor organoids from fresh pancreatic tumor tissue samples and patient-derived xenografts of pancreatic adenocarcinoma origin.
The development of tumor models for translational research. We use these models to test new drugs that can be applied in the clinic for personalized medicine. Advanced in vitro and in vivo models that have been developed from many different tumor types that are more physiological relevant than the 2D models that have traditionally been used in cancer research.
Design models that mimic the shape of the original organ, such as colon grips, are being used for in vitro models. Furthermore, these models and corresponding primary tissue are characterized using techniques, such as spatial transcriptomics, that allow specific areas and cell types within the tumor to be analyzed separately. The quality of the tissue is an important factor.
From prior treatment of the patients prior to harvesting, time of culture establishment, from tissue harvesting, tumor cell content and contamination by microorganisms, and non-desired cell populations such as fibroblasts. We have identified molecular subgroups of patients that may respond differently to therapy in the clinic. For this, we needed to develop preclinical models to test our hypothesis before moving to clinical trials.
Here, we try to address a problem of a standardized protocol that can be used for pancreatic tumor tissue, either directly from the primary tumor or from a PDX model. Many protocols have been reported, but this is the first one that has a corresponding video that is very useful for people starting to work with this type of culture. We also talk extensively about the many pitfalls and troubleshooting options that can be used.
View the full transcript and gain access to thousands of scientific videos
Overview
Tumor organoids have transformed cancer research, particularly in personalized medicine. This protocol outlines the establishment of tumor organoids from fresh pancreatic tumor tissues and patient-derived xenografts.
Key Study Components
Area of Science
- Cancer Research
- Personalized Medicine
- Organoid Models
Background
- Traditional 2D models are less physiologically relevant.
- In vitro and in vivo models are essential for drug testing.
- Organoids mimic the original tumor architecture.
- Spatial transcriptomics helps analyze specific tumor areas.
Purpose of Study
- To develop clinically relevant tumor models.
- To enhance drug testing for personalized medicine.
- To characterize tumor tissues effectively.
Methods Used
- Establishment of tumor organoids from fresh pancreatic tissues.
- Use of patient-derived xenografts.
- Application of spatial transcriptomics for analysis.
- Comparison of organoid models with traditional 2D cultures.
Main Results
- Organoids provide a more accurate representation of tumors.
- Characterization techniques reveal distinct tumor cell types.
- Models support the testing of new therapeutic strategies.
- Improved understanding of tumor biology through advanced models.
Conclusions
- Tumor organoids are pivotal for advancing cancer research.
- They facilitate personalized treatment approaches.
- Future studies can leverage these models for better outcomes.
Frequently Asked Questions
Executive Industry Relevance
Establishing pancreatic cancer-derived tumor organoids and fibroblasts from fresh tissue enables physiologically relevant preclinical models for translational oncology. These models support predictive confidence in drug response and mechanistic de-risking at the early discovery and target validation stages. Their reproducibility and alignment with patient tumor biology enhance portfolio decision-making and risk-adjusted advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in a disease-relevant 3D system.
- Supports functional target validation by recapitulating tumor microenvironment complexity.
- Facilitates mechanistic de-risking through patient-specific model fidelity.
- Improves predictive confidence for downstream translational studies.
Screening & Assay Development
- Provides validated organoid cultures for robust compound screening workflows.
- Enables assay standardization and reproducibility across biological replicates.
- Delivers quantitative outputs for comparative drug sensitivity and resistance profiling.
- Supports scalable preparation of models for high-content screening platforms.
Translational & Preclinical Research
- Aligns preclinical models with patient tumor heterogeneity for translational biomarker discovery.
- Maintains continuity from discovery through preclinical validation using patient-derived systems.
- Reduces translational risk by modeling cell-cell and tumor-stroma interactions ex vivo.
- Enables risk-adjusted advancement decisions based on physiologically relevant data.
Pipeline & Workflow Integration
This protocol positions organoid establishment at the interface of early discovery, lead identification, and preclinical research, supporting hypothesis testing and translational continuity.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification in a patient-relevant context.
- Screening: Provides reproducible, quantitative assay platforms for compound evaluation.
- Analytics: Enables measurement of treatment sensitivity, resistance, and cell-type specific responses.
- Translational Research: Bridges discovery and preclinical validation with models reflecting clinical tumor diversity.
- Enterprise Reuse: Establishes a reusable platform for ongoing translational oncology initiatives.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes organoid culture and assay workflows for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets.
Implementation Considerations
- Requires advanced cell culture expertise and access to fresh tumor tissue or PDX models.
- Needs specialized media, growth factor cocktails, and basement membrane matrices.
- Demands rigorous biobanking, storage, and quality control protocols.
- Must address variability in tissue quality, cellularity, and tumor grade.
- Adaptation across tumor types and laboratories may require protocol optimization.
